AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23527358 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants placed with adequate primary stability
Number of subjects: 37
Study 23527358 — intervention group
Group type: EXPERIMENTAL
Intervention: Implants placed in residual bone crests greater than 2 mm but less than 4 mm
Number of subjects: 37
Study 21851642 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-combination latanoprost 50 μg/mL and timolol 0.5 mg/mL (LTFC)
Number of subjects: 125
Study 21851642 — intervention group
Group type: COMPARATOR
Intervention: Unfixed combination of latanoprost (one drop in the evening) and timolol (one drop in the morning) (LTuFC)
Number of subjects: 125
Study 18799157 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehension of numerals and natural language quantifiers
Number of subjects: 0
Study 18799157 — intervention group
Group type: EXPERIMENTAL
Intervention: Truth-Value Judgment task
Number of subjects: 0
Study 18799157 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehension of numerals
Number of subjects: 0
Study 17500381 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept therapy
Number of subjects: 0
Study 15669455 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia (20 ml of 2% lidocaine with adrenaline 1 in 200000)
Number of subjects: 49
Study 15669455 — intervention group
Group type: COMPARATOR
Intervention: Combined 3-in-1 and sciatic nerve block (50 ml of 1% lignocaine with adrenaline 1 in 200000, using nerve stimulator)
Number of subjects: 49
Study 15669455 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia
Number of subjects: 49
Study 15669455 — intervention group
Group type: COMPARATOR
Intervention: Combined 3-in-1 and sciatic nerve block
Number of subjects: 49
Study 11463596 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (CPAP) treatment for 6 months
Number of subjects: 64
Study 11463596 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated OSA patients)
Number of subjects: 64
Study 11463596 — intervention group
Group type: COMPARATOR
Intervention: Nonapneic snorers (SN)
Number of subjects: 64
Study 9159445 — intervention group
Group type: EXPERIMENTAL
Intervention: Embryos with multinucleated blastomeres (MNB)
Number of subjects: 338
Study 9159445 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-cell stage embryos with a mononucleated and a binucleated blastomere
Number of subjects: 338
Study 9159445 — intervention group
Group type: COMPARATOR
Intervention: 2-cell embryos
Number of subjects: 338
Study 9159445 — intervention group
Group type: COMPARATOR
Intervention: 4-cell embryos
Number of subjects: 338
Study 7910231 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind, placebo-controlled food challenge
Number of subjects: 15000
Study 7910231 — intervention group
Group type: COMPARATOR
Intervention: Nationwide sample
Number of subjects: 15000
Study 7910231 — intervention group
Group type: COMPARATOR
Intervention: High Wycombe sample
Number of subjects: 15000
Study 7910231 — intervention group
Group type: COMPARATOR
Intervention: Population prevalence of reactions to eight foods
Number of subjects: 15000
Study 3591793 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Hemodialysis (HD)
Number of subjects: 11
Study 3591793 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic Hemodiafiltration (H HDF)
Number of subjects: 11
Study 31861028 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (n=20)
Number of subjects: 60
Study 31861028 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (n=20)
Number of subjects: 60
Study 31861028 — intervention group
Group type: COMPARATOR
Intervention: Control (Saline, n=20)
Number of subjects: 60
Study 30019653 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysialylated erythropoietin (PSA‐EPO), administered subcutaneously, aimed for once monthly administration.
Number of subjects: 0
Study 30019653 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysialylated deoxyribonuclease I (PSA‐DNase), details on administration not specified.
Number of subjects: 0
Study 27130143 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEPO (500 IU/kg, n = 366)
Number of subjects: 800
Study 27130143 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 377)
Number of subjects: 800
Study 25544167 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave combined with orthopaedic insole
Number of subjects: 153
Study 25544167 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal shock wave
Number of subjects: 153
Study 25544167 — intervention group
Group type: COMPARATOR
Intervention: Orthopaedic insole
Number of subjects: 153
Study 22686498 — intervention group
Group type: EXPERIMENTAL
Intervention: Inguinal sentinel lymphadenectomy (SLNE)
Number of subjects: 105
Study 20102855 — intervention group
Group type: COMPARATOR
Intervention: Weigh to Stay
Number of subjects: 113
Study 20102855 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal replacements (two meal replacements per day) with Weigh to Stay
Number of subjects: 113
Study 20102855 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal replacements (two meal replacements per day) with Weigh to Stay (intent-to-treat analysis)
Number of subjects: 113
Study 18072053 — intervention group
Group type: EXPERIMENTAL
Intervention: PillCam SB
Number of subjects: 40
Study 18072053 — intervention group
Group type: EXPERIMENTAL
Intervention: EndoCapsule
Number of subjects: 40
Study 18072053 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 40
Study 16077050 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Number of subjects: 120
Study 16077050 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 120
Study 12424547 — intervention group
Group type: COMPARATOR
Intervention: 0 mg/kg caffeine
Number of subjects: 30
Study 12424547 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg caffeine (at breakfast)
Number of subjects: 30
Study 12424547 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg caffeine (at breakfast)
Number of subjects: 30
Study 12424547 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg caffeine (60 min after breakfast)
Number of subjects: 30
Study 12424547 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg caffeine (after breakfast)
Number of subjects: 30
Study 10051499 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of recombinant vaccine (group 1)
Number of subjects: 318
Study 10051499 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of recombinant vaccine (group 2)
Number of subjects: 318
Study 10051499 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of plasma-derived vaccine (group 3)
Number of subjects: 318
Study 10051499 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 318
Study 8635039 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (80 mg/m2 iv loading dose followed by 20 mg/m2/hr) with dronabinol 5 mg/m2
Number of subjects: 126
Study 8635039 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine (6 mg/m2 intravenous loading dose followed by 1.5 mg/m2/hour) with dronabinol 5 mg/m2
Number of subjects: 126
Study 8635039 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (80 mg/m2 iv loading dose followed by 20 mg/m2/hr) without dronabinol
Number of subjects: 126
Study 8635039 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine (6 mg/m2 intravenous loading dose followed by 1.5 mg/m2/hour) without dronabinol
Number of subjects: 126
Study 8635039 — intervention group
Group type: EXPERIMENTAL
Intervention: Both metoclopramide and prochlorperazine
Number of subjects: 126
Study 1980697 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 500
Study 1980697 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 500
Study 1980697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study 6783059 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 17
Study 6783059 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (DSCG)
Number of subjects: 17
Study 6783059 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 6783059 — intervention group
Group type: COMPARATOR
Intervention: Exercise without preliminary treatment
Number of subjects: 17
Study 30640482 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT + MM (Cognitive Behavioral Therapy + Mindfulness Meditation)
Number of subjects: 404
Study 30640482 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT + PMR (Cognitive Behavioral Therapy + Progressive Muscle Relaxation)
Number of subjects: 404
Study 30640482 — intervention group
Group type: COMPARATOR
Intervention: AoC (Assessment-only Control)
Number of subjects: 404
Study 29157275 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination community-based intervention (CBI)
Number of subjects: 1080
Study 29157275 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 1080
Study 26017304 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 40 mg every 28 days
Number of subjects: 0
Study 26017304 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 40 or 60 mg every 28 days
Number of subjects: 0
Study 26017304 — intervention group
Group type: COMPARATOR
Intervention: Pasireotide
Number of subjects: 0
Study 24928359 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone tunnel technique
Number of subjects: 79
Study 24928359 — intervention group
Group type: COMPARATOR
Intervention: Tunnel-free technique
Number of subjects: 79
Study 22847485 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT), 8-session group format
Number of subjects: 0
Study 22847485 — intervention group
Group type: COMPARATOR
Intervention: Comparison condition (time-matched)
Number of subjects: 0
Study 19344195 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based case management program plus usual care
Number of subjects: 77
Study 19344195 — intervention group
Group type: COMPARATOR
Intervention: Usual clinic care alone
Number of subjects: 77
Study 16889931 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety Sensitivity Amelioration Training (ASAT)
Number of subjects: 404
Study 16889931 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 404
Study 14872148 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril (8 mg/d)
Number of subjects: 12218
Study 14872148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12218
Study 11476288 — intervention group
Group type: EXPERIMENTAL
Intervention: Total homocysteine (tHcy) levels
Number of subjects: 0
Study 9883785 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-Self Program (self-care intervention)
Number of subjects: 0
Study 7978427 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg R 80122
Number of subjects: 20
Study 7978427 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg enoximone
Number of subjects: 20
Study 2688778 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day methadone withdrawal programme
Number of subjects: 132
Study 2688778 — intervention group
Group type: COMPARATOR
Intervention: 21-day methadone withdrawal programme
Number of subjects: 132
Study 31898192 — intervention group
Group type: EXPERIMENTAL
Intervention: PAP-NAP
Number of subjects: 139
Study 30112930 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifitegrast ophthalmic solution 5.0%
Number of subjects: 2464
Study 30112930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2464
Study 28901935 — intervention group
Group type: EXPERIMENTAL
Intervention: Duodenum-preserving pancreatic head resection (DPPHR)
Number of subjects: 250
Study 28901935 — intervention group
Group type: COMPARATOR
Intervention: Partial pancreatoduodenectomy
Number of subjects: 250
Study 28901935 — intervention group
Group type: EXPERIMENTAL
Intervention: DPPHR
Number of subjects: 250
Study 25851895 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF) 5 μg/kg/q12h for 5 days
Number of subjects: 40
Study 25851895 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 25851895 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 40
Study 24201304 — intervention group
Group type: EXPERIMENTAL
Intervention: New Year recruitment period
Number of subjects: 0
Study 24201304 — intervention group
Group type: COMPARATOR
Intervention: Summer recruitment period
Number of subjects: 0
Study 24201304 — intervention group
Group type: COMPARATOR
Intervention: Fall recruitment period
Number of subjects: 0
Study 24201304 — intervention group
Group type: EXPERIMENTAL
Intervention: New Year participants
Number of subjects: 0
Study 21702706 — intervention group
Group type: EXPERIMENTAL
Intervention: Family involvement in care (FIC) intervention
Number of subjects: 116
Study 18063345 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapalene gel 0.1%
Number of subjects: 200
Study 18063345 — intervention group
Group type: COMPARATOR
Intervention: Gel vehicle
Number of subjects: 200
Study 16244099 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (essay, lecture, video, group discussions, self-test, instructions on BSEs)
Number of subjects: 172
Study 16244099 — intervention group
Group type: COMPARATOR
Intervention: Control condition (nutrition and exercise focus)
Number of subjects: 172
Study 16244099 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 172
Study 12584036 — intervention group
Group type: EXPERIMENTAL
Intervention: iv pamidronate 120 mg for Group I, 180 mg for Group II, 240 mg for Group III
Number of subjects: 68
Study 12584036 — intervention group
Group type: EXPERIMENTAL
Intervention: iv pamidronate
Number of subjects: 68
Study 10874063 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral anticoagulants for six weeks
Number of subjects: 854
Study 10874063 — intervention group
Group type: COMPARATOR
Intervention: Oral anticoagulants for six months
Number of subjects: 854
Study 10874063 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of cancer
Number of subjects: 854
Study 10874063 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized incidence ratio for newly diagnosed cancer
Number of subjects: 854
Study 10874063 — intervention group
Group type: EXPERIMENTAL
Intervention: Urogenital cancers
Number of subjects: 854
Study 9086359 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole (antiglutamate agent)
Number of subjects: 0
Study 1577047 — intervention group
Group type: EXPERIMENTAL
Intervention: Adinazolam (5, 10, 15, 20 mg)
Number of subjects: 6
Study 1577047 — intervention group
Group type: EXPERIMENTAL
Intervention: NDMAD (10, 20, 30, 40 mg)
Number of subjects: 6
Study 1577047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2857036 — intervention group
Group type: EXPERIMENTAL
Intervention: Eproxindine
Number of subjects: 1
Study 2857036 — intervention group
Group type: COMPARATOR
Intervention: Flupenthixol (depot injection)
Number of subjects: 1
Study 30795753 — intervention group
Group type: EXPERIMENTAL
Intervention: Saffron (100 mg/d)
Number of subjects: 80
Study 29966188 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic rehabilitation (30 minutes per session, five times a week for 3 weeks)
Number of subjects: 35
Study 29966188 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation program (five times a week for 3 weeks)
Number of subjects: 35
Study 29966188 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic rehabilitation and conventional rehabilitation
Number of subjects: 35
Study 26303968 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Total(™) (CT)
Number of subjects: 72
Study 26303968 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluor Protector Gel(™) (FPG)
Number of subjects: 72
Study 26303968 — intervention group
Group type: COMPARATOR
Intervention: Control (G1)
Number of subjects: 72
Study 25379427 — intervention group
Group type: EXPERIMENTAL
Intervention: computer‐based facial affect training
Number of subjects: 57
Study 25379427 — intervention group
Group type: EXPERIMENTAL
Intervention: targeted cognitive training on auditory‐verbal discrimination and working memory
Number of subjects: 57
Study 25379427 — intervention group
Group type: COMPARATOR
Intervention: treatment as usual
Number of subjects: 57
Study 22286957 — intervention group
Group type: COMPARATOR
Intervention: Low-dose acute tryptophan depletion (LD-ATD) with no tryptophan (T−)
Number of subjects: 19
Study 21638967 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% Sodium hypochlorite (NaOCl) during instrumentation and a 15 minutes final irrigation with 2% iodine potassium iodide (IKI)
Number of subjects: 72
Study 21638967 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% Sodium hypochlorite (NaOCl) during instrumentation and a 5 minutes final irrigation with 2% iodine potassium iodide (IKI)
Number of subjects: 72
Study 21638967 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% Sodium hypochlorite (NaOCl) during instrumentation
Number of subjects: 72
Study 21638967 — intervention group
Group type: COMPARATOR
Intervention: Sterile distilled water (control)
Number of subjects: 72
Study 18325918 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian function suppression (OFS) plus tamoxifen for 5 years
Number of subjects: 1317
Study 18325918 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian function suppression (OFS) plus exemestane for 5 years
Number of subjects: 1317
Study 18325918 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chemotherapy)
Number of subjects: 1317
Study 15979652 — intervention group
Group type: EXPERIMENTAL
Intervention: NTX plus prazepam (one 10-mg tablet twice daily)
Number of subjects: 56
Study 15979652 — intervention group
Group type: EXPERIMENTAL
Intervention: NTX alone (one 50-mg tablet daily)
Number of subjects: 56
Study 15979652 — intervention group
Group type: EXPERIMENTAL
Intervention: NTX plus placebo (one 50-mg tablet daily plus one tablet twice daily)
Number of subjects: 56
Study 15979652 — intervention group
Group type: COMPARATOR
Intervention: No pharmacological treatment (control group)
Number of subjects: 56
Study 11937475 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagenase
Number of subjects: 135
Study 11937475 — intervention group
Group type: COMPARATOR
Intervention: Fibrinolysin/deoxyribonuclease
Number of subjects: 135
Study 11035992 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatments (hysterectomy, abdominal myomectomy, laparoscopic myomectomy, myolysis)
Number of subjects: 0
Study 11035992 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical treatments (uterine artery embolization, medical therapy)
Number of subjects: 0
Study 11035992 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized clinical trials
Number of subjects: 0
Study 8813271 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IvIg) 0.4 g per kg body weight
Number of subjects: 30
Study 8813271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8813271 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IvIg)
Number of subjects: 30
Study 1366259 — intervention group
Group type: COMPARATOR
Intervention: PROBE study design
Number of subjects: 0
Study 1366259 — intervention group
Group type: COMPARATOR
Intervention: Classical double-blind design
Number of subjects: 0
Study 2931947 — intervention group
Group type: EXPERIMENTAL
Intervention: mianserin
Number of subjects: 0
Study 2931947 — intervention group
Group type: COMPARATOR
Intervention: zimeldine
Number of subjects: 0
Study 29546320 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training with Caloric Restriction (RT+CR; n=15)
Number of subjects: 31
Study 29546320 — intervention group
Group type: COMPARATOR
Intervention: Resistance Training without Caloric Restriction (RT; n=16)
Number of subjects: 31
Study 30221336 — intervention group
Group type: COMPARATOR
Intervention: Cepodoxime (100 mg twice per day)
Number of subjects: 55
Study 30221336 — intervention group
Group type: EXPERIMENTAL
Intervention: Cepodoxime (100 mg) and aceclofenac (100 mg twice per day)
Number of subjects: 55
Study 30221336 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 55
Study 26807853 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group discussions
Number of subjects: 25
Study 24351875 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Glycemic Index (LGI) dietary advice
Number of subjects: 691
Study 24351875 — intervention group
Group type: COMPARATOR
Intervention: Healthy Eating (HE) advice
Number of subjects: 691
Study 23548570 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 71
Study 23548570 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 71
Study 23548570 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin or Pregabalin
Number of subjects: 71
Study 20164474 — intervention group
Group type: EXPERIMENTAL
Intervention: Coached group
Number of subjects: 215
Study 20164474 — intervention group
Group type: COMPARATOR
Intervention: Not-coached group
Number of subjects: 215
Study 18826865 — intervention group
Group type: EXPERIMENTAL
Intervention: Grape juice with diltiazem 180 mg
Number of subjects: 12
Study 18826865 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange juice with diltiazem 180 mg
Number of subjects: 12
Study 18826865 — intervention group
Group type: COMPARATOR
Intervention: Water with diltiazem 180 mg
Number of subjects: 12
Study 15805130 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention PCG/Ts received profiles with information on hospital admissions for accidental injury and their costs.
Number of subjects: 0
Study 15805130 — intervention group
Group type: COMPARATOR
Intervention: Control PCG/Ts did not receive the intervention.
Number of subjects: 0
Study 12576870 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg. atrasentan
Number of subjects: 288
Study 12576870 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg. atrasentan
Number of subjects: 288
Study 12576870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study 10588501 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidized regenerated cellulose
Number of subjects: 30
Study 10588501 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable gelatin sponge
Number of subjects: 30
Study 10588501 — intervention group
Group type: COMPARATOR
Intervention: Sterile gauze with external pressure (control)
Number of subjects: 30